Vivek K. Arora, MD, PhD - 2014 Young Investigator Award
"Oncogenic and Therapeutic Potential Nuclear Receptors in Bladder Cancer"
Awarded a $75,000 Young Investigator Award.
Modern genomic characterization of tumors is not only revealing the fundamental basis for cancer, but is also illuminating rational drug targets to pursue. There are now multiple examples of highly successful anti-cancer drugs that were developed to target the abnormal products of mutated cancer genes. Encouragingly, data amassed from recent bladder cancer sequencing efforts has revealed targetable cancer-causing mutations. As a particularly exciting example, ~25% of bladder cancers have gene alterations in a class of proteins called nuclear receptors. Nuclear receptors are attractive drug targets because they are highly amenable to modulation with drugs and there is a rich understanding of the types of chemicals that can modulate their function. While the genetic evidence is compelling, it remains to be comprehensively proven that these targets warrant a full drug development effort. I am proposing a series of experiments to validate aberrant nuclear receptors as worthwhile drug targets.
The Cancer Research Foundation has focused attention on cancer and raised money for life-giving research. We...pay tribute to the scientists who have dedicated themselves to finding a cure and to meet the young researchers who are the next generation of fighters against this disease. The message we send today is that those who suffer from cancer are not alone and that together we can work toward a solution."Richard M. Daley
Mayor, City of Chicago
May 20, 1997